Abstract-Voltage-gated K ϩ channels (K V ) and thromboxane A 2 (TXA 2 ) play critical roles in controlling pulmonary arterial tone under physiological and pathological conditions. We hypothesized that TXA 2 might inhibit K V channels, thereby establishing a link between these two major pathogenic pathways in pulmonary hypertension. The TXA 2 analogue U46619 inhibited I K(V) (E max ϭ56.1Ϯ3.9%, EC 50 ϭ0.054Ϯ0.019 mol/L) and depolarized pulmonary artery smooth muscle cells via activation of TP receptors. In isolated pulmonary arteries, U46619 simultaneously increased intracellular Ca 2ϩ concentration and contractile force, and these effects were inhibited by nifedipine or KCl (60 mmol/L). U46619-induced contractions were not altered by the inhibitors of tyrosine kinase genistein or Rho kinase Y-27632 but were prevented by the nonselective protein kinase C (PKC) inhibitors staurosporine and calphostin C. Furthermore, these responses were sensitive to Gö-6983 but insensitive to bisindolylmaleimide I and Gö-6976. Based on the specificity of these drugs, we suggested a role for an atypical PKC in U46619-induced effects. Thus, treatment with a PKC pseudosubstrate inhibitor markedly prevented the vasoconstriction, the inhibition of I K(V) , and the depolarization induced by U46619. Western blots showed a transient translocation of PKC from the cytosolic to the particulate fraction on stimulation with U46619. These results indicate that TXA 2 inhibits I K(V) , leading to depolarization, activation of L-type Ca 2ϩ channels, and vasoconstriction of rat pulmonary arteries. We propose PKC as a link between TP receptor activation and K V channel inhibition. 
T hromboxane A 2 (TXA 2 ) is a prostanoid synthesized by cyclooxygenase with potent vasoconstrictor, mitogenic, and platelet aggregant properties. 1 The vasoconstrictor effects of TXA 2 are particularly pronounced in the pulmonary vascular bed, where it participates in the control of vessel tone under physiological and pathological situations. In fact, TXA 2 has been involved in several forms of human and experimental pulmonary hypertension, including primary 2 and secondary pulmonary hypertension induced by sepsis, endotoxemia, heparin/protamine, leukotriene D 4 , microembolism, and ischemia-reperfusion. [3] [4] [5] [6] [7] [8] TXA 2 contracts vascular smooth muscle by binding to specific G q/11 protein-coupled receptors (TP receptors), which leads to an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) and sensitization of the contractile proteins to Ca 2ϩ . 9 -12 Activation of TP receptors is also involved in the vasoconstrictor effects of several isoprostanes, a novel class of arachidonic acid metabolites generated by oxygen free radical-mediated peroxidation of membrane phospholipids, used as markers for many disease states, including pulmonary hypertension. 13 The signaling pathways mediating TP receptor-induced contraction remain controversial, because a variety of protein kinases, such as protein kinase C (PKC), Rho kinase, and tyrosine kinases, have been shown to be involved. 9, 10, 12 K ϩ channels play an essential role in regulating resting membrane potential, [Ca 2ϩ ] i , and contraction of vascular smooth muscle. 14 -18 Activation of K ϩ channels leads to hyperpolarization, whereas their inhibition causes membrane depolarization, activation of voltage-gated L-type Ca 2ϩ channels, increase in [Ca 2ϩ ] i , and vasoconstriction. Different types of K ϩ channels have been identified in pulmonary artery smooth muscle cells (PASMCs), including voltage-gated K ϩ channels (K V ), large-conductance Ca 2ϩ -activated channels (BK Ca ), and ATP-dependent channels (K ATP ). 14, [17] [18] [19] There is increasing interest in K V channels in the pulmonary circulation because of several different facts. First, they make a substantial contribution to whole-cell K ϩ conductance and resting membrane potential in PASMCs. 14, 15, 18 Second, they are modulated by hypoxia and vasoactive factors such as nitric oxide, endothelin-1, and angiotensin II. 14,19 -21 Finally, decreased expression or function of K V channels in PASMCs has been involved in the pathogenesis of primary and anorexigen-induced pulmonary hypertension. 14, [22] [23] [24] Very little is known about the effects of TXA 2 on vascular K ϩ channels. It has been reported that TXA 2 analogues inhibit the activity of BK Ca channels in bronchial and coronary arteries, 25, 26 whereas their effects on vascular K V channels are unknown. We hypothesized that TXA 2 might inhibit K V channels, thereby establishing a link between these two pathogenic pathways in pulmonary hypertension. Therefore, in the present study we have analyzed the effects of the TXA 2 analogue U46619 on the current flowing through K V channels (I K(V) ) recorded in rat PASMCs using the whole-cell configuration of the patch-clamp technique. The role of K V channels in TXA 2 -induced pulmonary vasoconstriction has also been studied in isolated pulmonary arteries (PAs). Our results indicate that U46619 inhibits K V channels, leading to depolarization of PASMCs, an increase in [Ca 2ϩ ] i , and vasoconstriction in PA. Furthermore, we provide evidence for the role of PKC as the link between TXA 2 receptor activation and inhibition of K V channels.
Materials and Methods
All experiments were carried out in accordance with the European Animals Act 1986 (Scientific Procedures) and approved by our institutional review board.
Reagents
Drugs were obtained from Sigma, except nifedipine (Bayer España), Y-27632 (Tocris Cookson), fura-2 AM, calphostin C, Gö-6976, Gö-6983, PKC pseudosubstrate inhibitor, and secondary horseradish peroxidase-conjugated antibodies (Calbiochem). Polyclonal rabbit antibodies were from Santa Cruz Biotechnology.
Tissue Preparation and Cell Isolation
Second-to third-order branches of the PA (internal diameter, 0.5 to 1 mm) isolated from male Wistar rats (250 to 300 g; ANUC, Universidad Complutense, Madrid, Spain) were dissected into a nominally calcium-free physiological salt solution (Ca 2ϩ -free PSS) of the following composition (in mmol/L): NaCl 130, KCl 5, MgCl 2 1.2, glucose 10, and HEPES 10 (pH 7.3 with NaOH). Endotheliumdenuded PAs were cut into small segments (2ϫ2 mm), and cells were isolated in Ca 2ϩ -free PSS containing (in mg/mL) papain 1, dithiothreitol 0.8, and albumin 0.7. Cells were stored in Ca 2ϩ -free PSS (4°C) and used within 8 hours of isolation.
Contractile Tension Recording
Contractile responses in endothelium-denuded PA rings were recorded as previously reported. 9, 27 Arteries were stimulated with U46619 (0.1 mol/L) and, once a stable contraction was reached, were washed with Krebs solution for 30 minutes. A second stimulation with U46619 was elicited in the absence of treatment (controls) or after 30 minutes of treatment with different drugs. The values of the second contraction were expressed as a percentage of the initial response to the agonist and normalized to the values obtained in control experiments.
Simultaneous [Ca 2؉ ] i and Tension Recording
PA rings were incubated for 2 to 3 hours in Krebs solution containing fura-2 acetoxymethylester (5 mol/L) and Cremophor EL (0.05%) and then mounted in a bath that allows the estimation of changes in the fluorescence intensity of fura-2 and force development simultaneously. 9, 28 The absolute values of [Ca 2ϩ ] i were estimated using the Grynkiewicz equation. 9, 29 
Electrophysiological Studies
Membrane currents were measured using the whole-cell configuration of the patch-clamp technique, 30 
g/mL aprotinin, 4 g/mL leupeptin, 4 g/mL N␣-p-tosyl-L-lysine chloromethyl ketone, 5 mmol/L NaF, 10 mmol/L Na 2 MoO 4 , 1 mmol/L NaVO 4 , 0.5 mmol/L phenylmethanesulfonyl fluoride, and 10 nmol/L okadaic acid. The homogenate was centrifuged at 100 000g for 30 minutes. The supernatant was collected (cytosolic fraction), and the pellet was resuspended in 200 L of the same buffer containing nonidet P-40 1% and gently shaken for 30 minutes at 4°C and again centrifuged at 100 000g for 30 minutes. The pellet was discarded, and the supernatant was collected (particulateenriched fraction). The enrichment of the subcellular fractions was evaluated by measuring the levels of cytosolic and membrane markers. Western blotting was performed with 10 g of protein from the supernatant per lane. SDS-PAGE (7.5% acrylamide) electrophoresis was performed using the method of Laemmli in a mini-gel system (Bio-Rad). The proteins were transferred to PVDF membranes overnight at 4°C and incubated with rabbit anti-PKC, anti-PKC, or anti-P-T410-PKC primary antibodies and secondary anti-rabbit horseradish peroxidase-conjugated antibodies. The bands were visualized by chemoluminescence (ECL, Amersham).
Statistical Analysis
Data are expressed as meanϮSEM; n indicates the number of arteries or cells tested from different animals. Statistical analysis was performed using Student's t test for paired observations or one-way ANOVA followed by a Newman-Keuls test. Differences were considered statistically significant when PϽ0.05.
Results

Effects of the TXA 2 Analogue U46619 on I K(V) and Membrane Potential
The average cell capacitance of the freshly isolated rat PASMC was 17.4Ϯ0.6 pF (nϭ42). I K(V) was recorded under essentially Ca 2ϩ -free conditions, and EGTA and ATP were included in the pipette solution to minimize the component of ATP-dependent (I K(ATP) ) and Ca 2ϩ -activated (I BK(Ca) ) K ϩ currents. Under these conditions, when cells were voltageclamped at Ϫ60 mV, the application of 200-ms depolarizing pulses to test potentials from Ϫ60 to ϩ50 mV in 10-mV increments induced a K ϩ current ( Figure 1A ), which activated at potentials positive to Ϫ30 mV and was usually reproducible for at least 1 hour. This current was essentially abolished by the K V channel inhibitor 4-aminopyridine (1 mmol/L, Figures 1F and 1G ), indicating that it was evoked by the activation of K V channels. U46619 inhibited I K(V) in a concentration-dependent manner ( Figures 1A and 1B) . The onset of the response to U46619 was fast (20 to 30 seconds) and reached a stable response within 2 to 3 minutes. The concentration-response curve for the inhibition of I K(V) by U46619 at test potentials of ϩ50 mV was fitted to a Hill equation, leading to E max and EC 50 values of 56.1Ϯ3.9% and 0.054Ϯ0.019 mol/L, respectively ( Figure 1C ). The magnitude of this inhibition was similar at the potentials tested, indicating a voltage-independent blockade ( Figure 1D ). In addition, U46619 (0.1 and 1 mol/L) significantly depolarized PASMCs in a concentration-dependent manner ( Figure  1E ).
In the presence of the TXA 2 receptor antagonist SQ-29548 (3 mol/L), U46619 (0.1 mol/L) did not modify the K V currents or the membrane potential in isolated PASMCs (Figures 2A and 2B ). These results indicated that the electrophysiological effects induced by U46619 were mediated through the activation of TP receptors.
Effects of U46619 on Contraction and [Ca 2؉ ] i : Role of L-Type Ca 2؉ Channels
Stimulation of endothelium-denuded PA rings with U46619 (0.1 mol/L, which produced Ϸ50% of the maximal response) induced a sustained contractile response of 185Ϯ23 mg (nϭ10), which was suitably reproduced after a 30-minute washout (109Ϯ4% of the first contraction, PϾ0.05). Pretreatment with 3 mol/L SQ-29548 before the second addition of U46619 completely abolished the vasoconstriction ( Figure  2C ). Depolarization resulting from U46619-induced inhibition of K V channels might increase vascular tone by promoting Ca 2ϩ entry through voltage-gated L-type Ca 2ϩ channels. To test the possibility that U46619 could be modulating L-type Ca 2ϩ channels not only via membrane depolarization but also directly, its effects were analyzed on L-type Ca 2ϩ currents recorded in isolated PASMCs. Figure 4A shows traces of Ca 2ϩ currents elicited when stepping from Ϫ60 to ϩ10 mV. The current activated at ϷϪ27 mV reached a maximum at ϩ10 mV ( Figure 4B ) and was not significantly affected by U46619 (0.1 mol/L) but was completely abolished by nifedipine (0.1 mol/L).
Role of Protein Kinases on U46619-Induced Effects
To additionally assess the mechanisms involved in U46619-induced contraction, PAs were incubated with different protein kinase inhibitors before the second addition of the agonist. As shown in Figure 5A , neither the tyrosine kinase inhibitor genistein (10 mol/L) nor the Rho kinase inhibitor Y-27632 (1 mol/L) modified U46619-induced contraction, whereas the PKC inhibitors staurosporine (0.01 mol/L) and calphostin C (1 mol/L) markedly attenuated the response to the TXA 2 analogue. Because staurosporine is a nonselective inhibitor of PKC and may also directly affect contractile proteins (eg, it inhibits myosin light chain kinase 31 ), we analyzed its effects on 4-aminopyridine-induced contractions. At 10 mmol/L, 4-aminopyridine elicited a contractile response of 159Ϯ14 mg (nϭ8). Staurosporine (0.01 mol/L) did not affect the contraction induced by 4-aminopyridine (162Ϯ15 mg; nϭ9; PϾ0.05), suggesting that at this concentration the drug had no direct effect on contractile proteins.
In PASMCs, Y-27632 (1 mol/L) did not significantly modify the membrane potential or I K(V) and did not alter the depolarizing (not shown) or K V channel inhibitory effects 
Role of PKC in U46619-Induced Effects
In view of the preceding data, we performed pharmacological studies with isotype-selective PKC inhibitors to evaluate the involvement of specific PKC isoforms in U46619-induced contractions. The inhibitors used were bisindolylmaleimide I, which at the concentration tested shows selectivity for the conventional PKC (cPKC) isoforms (␣, ␤I, ␤II, and ␥) and for some novel PKC (nPKC) isoforms (␦ and ⑀); Gö-6976, which inhibits cPKC isoforms and PKC; and Gö-6983, which preferentially inhibits cPKC, some nPKC, and the atypical (aPKC) PKC but not PKC. 31, 32 No changes were observed in U46619-induced contraction when PAs were pretreated with 1 mol/L bisindolylmaleimide I or 0.01 mol/L Gö-6976 ( Figure 6A ). However, exposure to Gö-6983 (0.01 mol/L) markedly inhibited U46619-induced contraction. Because the only isoform known to be sensitive to Gö-6983 and insensitive to the other two drugs is PKC, we hypothesized that this aPKC might be involved in the responses induced by U46619. Therefore, we examined the effects of a PKC pseudosubstrate inhibitor (PKC-PI, 10 mol/L). Figure 6A shows that PKC-PI produced an inhibition of U46619-induced pulmonary vasoconstriction similar to that induced by Gö-6983.
In PASMCs, U46619 did not alter I K(V) in the presence of 0.1 mol/L Gö-6983 (which very slightly reduced I K(V) by 10.7Ϯ6.8%, PϾ0.05, Figure 6B ). Similarly, in cells dialyzed with an internal solution containing 0.1 mol/L PKC-PI, the addition of U46619 had no effect on I K(V) ( Figure 6C ) or membrane potential (EmϭϪ47.2Ϯ1.5 and Ϫ47.9Ϯ1.3 mV before and after adding U46619, respectively). Altogether, these results indicated a key role of PKC in TXA 2 -induced inhibition of I K(V) , depolarization, and contraction of PA.
Subcellular Distribution of aPKC
Numerous reports in the literature using antibodies raised against the C-terminal domain of PKC found two bands of Ϸ75 to 80 kDa in fibroblasts, rabbit and ferret aorta, rat cardiac myocytes, PC12 cells, murine epidermis, basophilic RBL-2H3 cells, Jurkat T lymphoma cells, rat embryo fibroblasts, NIH 3T3 cells, the J774 macrophage cell line, the ␣T3-1 gonadotroph-derived cell line, rat brain, and bovine kidney cells (Reference 33 and references therein). The upper band is Ca 2ϩ -dependent, can be downregulated by phorbol esters, and is actually considered a cPKC. 33 Western blots of homogenates from rat PA using polyclonal rabbit antibody directed toward the C-terminal peptide of PKC also recognized two bands of Ϸ81 and 75 kDa ( Figure 6D ). This antibody cross-reacts with the aPKC/. However, the expression of this aPKC was negligible using a specific anti-PKC/ antibody toward the amino acids 168 to 243 of PKC of human origin (equivalent to rodent PKC). Furthermore, an antibody directed toward the phosphorylated activation loop (T410) of PKC clearly identified the lower band even when the heavier one was also present in some blots. This indicates that an aPKC, most probably PKC, is strongly expressed and is at least partly phosphorylated at T410 in resting rat PA. Because the activity of PKC is mostly controlled by its intracellular compartmentalization, we analyzed its subcellular distribution and its possible translocation on stimulation with U46619. The 81-kDa band was located mostly in the particulate fraction (82Ϯ5%), and its cytosolic/ particulate distribution did not change in PA stimulated with U46619. However, the 75-kDa band was less abundant in the particulate fraction (38Ϯ7%) and was rapidly but transiently translocated to the membrane fraction on U46619 stimulation ( Figure 6D ).
Discussion
In the present study, we have examined the effects of the TXA 2 analogue U46619 on K V channels in freshly isolated 
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PASMCs and its role in [Ca 2ϩ ] i and contraction in rat PA. We have demonstrated for the first time that U46619, through the activation of TP receptors, inhibited I K(V) and depolarized PASMCs in a concentration-dependent manner. These effects were totally abolished by nonselective PKC inhibitors and by selective inhibition of aPKCs. Additionally, the U46619-induced increases in [Ca 2ϩ ] i and contraction of the PA were markedly attenuated by L-type Ca 2ϩ channel blockade, although this vasoconstrictor did not directly affect L-type Ca 2ϩ currents. PKC was strongly expressed in PA and was translocated on stimulation with U46619, whereas expression of the other aPKC (PKC/) was negligible. All of these results indicate that U46619, via PKC-dependent pathway, inhibits K V channel activity and causes membrane depolarization, leading to the activation of L-type Ca 2ϩ channels, increase in [Ca 2ϩ ] i , and contraction of PASMCs. Membrane potential plays an essential role in regulating vascular diameter through the control of Ca 2ϩ influx and, therefore, [Ca 2ϩ ] i . In PASMCs, the resting membrane potential seems to be predominantly regulated by K V channels. 14 widely assumed to involve a direct activation of TXA 2 on L-type Ca 2ϩ channels. 11 However, such assumption has never been demonstrated, and, in fact, a blockade of these channels by TXA 2 agonists has been described in rat hippocampal CA1 neurons. 34 In the present study, L-type Ca 2ϩ currents were not affected by U46619 but were abolished by nifedipine. Therefore, our results are consistent with earlier studies demonstrating the involvement of L-type Ca 2ϩ channels in TXA 2 -induced vasoconstriction 11 but highlight a relevant role for K V channels as key modulators linking TP receptors to L-type Ca 2ϩ channels in rat PA. However, our results cannot rule out that other mechanisms may also contribute to the contraction induced by the activation of TP receptors. Thus, there is a residual component of the contraction that is independent of changes in [Ca 2ϩ ] i (ie, implies Ca 2ϩ sensitization 9, 10 ) and on the signaling events described herein.
TXA 2 -induced pulmonary vasoconstriction has been shown to be mediated through different intracellular signaling cascades, such as PKC, tyrosine kinase, and Rho kinase. 9, 10, 12, 27 In the present study, the analysis of the signaling pathways involved in TXA 2 -induced effects revealed a lack of involvement of tyrosine and Rho kinases. However, the vasoconstrictor and electrophysiological effects of U46619 were attenuated by the nonselective PKC inhibitors staurosporine and calphostin C. Because staurosporine per se did not modify K V currents or the contraction induced by 4-aminopyridine, the role of PKC in modulating K V channels seems to be dependent on the activation of TP receptors. PKC 
represents a family of several isoforms that can be divided into cPKC (␣, ␤I, ␤II, and ␥), nPKC (␦, ⑀, , and ), and aPKC ( and /) isoforms. 31, 32 The former group includes Ca 2ϩ -dependent isoforms, whereas nPKC and aPKC are Ca 2ϩ -independent. Several isoforms (␣, ␤, ␦, ⑀, and ) seem to coexist in vascular smooth muscle cells, 36, 37 and their modulation may account for the responses of vasoconstrictor agents such as angiotensin II, norepinephrine, and endothelin-1. 35, 36, 38 The contractile response to U46619 was sensitive to Gö-6983 (which preferentially inhibits cPKC, ␦, and isoforms) but insensitive to bisindolylmaleimide I or to Gö-6976 at concentrations at which cPKC, ␦, ⑀, and isoforms should be substantially blocked. 31 These results suggest a role for an aPKC in TXA 2 -induced effects. This proposal is additionally supported by the fact that TXA 2 -induced inhibition of K V channels was observed under Ca 2ϩ -free conditions. A pseudosubstrate inhibitor peptide, highly specific for PKC, markedly inhibited the effects induced by U46619 on K V channels and contractile force, which indicated a functional role for PKC in the signal transduction after TP receptor activation. In agreement with our results, PKC is also involved in TXA 2 -induced apoptosis in ventricular myocytes. 39 The expression of PKC was confirmed by Western blot analysis in rat PA (present results) and in cultured canine pulmonary vascular smooth cells 36 using an antibody directed to the C-terminal peptide of PKC, which shows crossreactivity with PKC/. However, the expression of PKC / was negligible using the specific anti-PKC/ antibody, suggesting that the aPKC in this tissue is mainly PKC. Furthermore, the results obtained with an antibody directed toward the phosphorylated activation loop (T410) of PKC indicate that this kinase is at least partly phosphorylated at T410 in PA. Another piece of evidence in favor of the involvement of PKC comes from the results of the transient translocation of PKC from the cytosolic to the particulateenriched fraction on stimulation with U46619.
K V channels are composed by pore-forming K V␣ and modulatory K V␤ subunits. 16 The ␤-subunits of K V channels may play an important role in modulating the gating properties of ␣-subunits. Interestingly, PKC, via PKC-interacting proteins (ZIP1, ZIP2, and ZIP3) acting as scaffolds, has been shown to phosphorylate the auxiliary K V␤ 2-subunit, 40, 41 whereas the consequences of this phosphorylation on K V function were not analyzed. Therefore, we suggest that after TP receptor activation, the translocation of PKC to the membrane may facilitate its coupling with K V channels. ZIPs, which dramatically enhance phosphorylation of K V subunits, are attractive scaffold candidates in this interaction.
Increased activity of TXA 2 is associated with several forms of pulmonary hypertension. [1] [2] [3] [4] [5] [6] [7] [8] It is interesting to note that calcium channel blockers are first-choice drugs in the treatment of pulmonary hypertension. 23, 42 The present results demonstrate that PKC translocation, K V channel inactivation, membrane depolarization, and L-type Ca 2ϩ channel activation are key events mediating TXA 2 -induced pulmonary vasoconstriction, establishing the rationale for the use of calcium channel blockers in pulmonary hypertension associated with increased vasoconstrictors such as TXA 2 and isoprostanes activating TP receptors.
In conclusion, we demonstrate that in intact PAs and freshly isolated PASMCs, TXA 2 , via activation of TP receptors, inhibits K V channels, leading to membrane depolarization, activation of L-type Ca 2ϩ channels, elevation of [Ca 2ϩ ] i , and vasoconstriction. PKC seems to play a major role as a link between TP receptor activation and K V channel inhibition.
